WillItSurvive
Financial data and information services · United States

IQVIA Holdings

iqvia.com ↗

Runs clinical trials and drug commercialization data for most of the world's big pharma companies.

Hard to displace
Assessed 20 July 2026 · Evidence as of 20 July 2026
Strong structural protection; the business model survives ai pressure.
On the recordSince 20 July 2026 · Checkable from July 27-28, 2026 · Every call on the record Checkpoint: Q2 2026 earnings report and Rose v. IQVIA amended complaint deadline
The call

IQVIA sits on patient data and pharma contracts that neither AI labs nor rival vendors can easily copy, while debt and litigation are the parts actually worth watching.

IQVIA helps pharmaceutical companies run clinical trials and analyze patient data. It's difficult for competitors like Parexel or Charles River to copy because IQVIA has spent decades building a huge, licensed database of patient information, plus long-term contracts with nearly all major drug makers and complex regulatory compliance systems (FDA, HIPAA, GDPR rules) that lock clients in. The company is also using AI to speed up its own internal work while keeping exclusive control of its patient data. The big question is whether IQVIA can sell its new AI tools as a separate product at higher prices, rather than bundling them into existing contracts where they just squeeze profit margins lower, which the company will reveal in late 2026.

Why
01
AI pressure: None apparent. No AI lab can pull IQVIA's licensed patient records or take on clinical-trial liability, so IQVIA is deploying its own agents instead of losing to someone else's. Could AI do the core job? Unlikely.
02
Bigger players: None apparent. Veeva competes on software workflow but does not hold IQVIA's patient data or trial-liability contracts with top pharma. Could a giant copy it? No, they are blocked.
03
What protects it. Decades of licensed patient records plus multi-year trial contracts with 19 of the top 20 pharma companies.
What would change this call
IQVIA reports two consecutive quarters of backlog decline from the $34.2B record. would suggest pharma sponsors are slowing or redirecting contract awards.
A top-4 pharma company publicly drops IQVIA data licensing for a direct AI-model-lab deal. would show the patient-data moat is being bypassed.
IQVIA.ai launches as a separately priced platform in its Q4 2026 roadmap release. would show AI tools are monetized as growth, not just an internal cost offset.
Key numbers
  • Backlog $34.2B (2026-05-29)
  • Net leverage 3.63x EBITDA (2025-12-31)
  • Q1 2026 revenue $4.15B, up 8.4% (2026-Q1)
Named risks
  • Net leverage of 3.63x EBITDA plus ~$80M 2026 interest expense step-up pressuring margins. Severity: medium
  • Active Rose et al. v. IQVIA litigation with amended complaint due July 27, 2026. Severity: medium
  • Antitrust scrutiny on future M&A after FTC blocked DeepIntent deal in January 2024. Severity: medium
  • Integration execution risk from Cedar Gate ($750M) and Charles River asset acquisitions. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
ICON plccontestingBig Four CRO market share split ~35-40% among IQVIA, ICON, PPD/Thermo Fisher, Parexel as of 2026-03
Parexel InternationalcontestingPE-backed rival competing in same full-service CRO Big Four tier, 2026-03
Thermo Fisher (PPD)contestingBig Four CRO peer competing on trial execution scale, 2026-03
Veeva Systemsgaining onAdjacent life-sciences software rival compared directly to IQVIA in analytics, 2026-05-29
Questions people ask
Is IQVIA Holdings profitable in 2026?
Yes. IQVIA generated free cash flow of $2.051 billion in FY2025 (99% of adjusted net income) on revenue of $16.310 billion, and Q1 2026 revenue rose 8.4% YoY to $4.15 billion with EPS of $2.90, beating consensus, per its February 2026 earnings report.
Could AI replace IQVIA's clinical research business?
Unlikely soon. IQVIA's moat rests on licensed access to over 1 billion de-identified patient records, FDA/HIPAA/GDPR compliance infrastructure, and preferred-provider contracts with 19 of the top 20 pharma firms (company-claimed, July 2026), none of which a generic AI model can replicate or assume liability for.
Who is IQVIA's biggest competitor?
IQVIA competes in the 'Big Four' CRO market with ICON plc, Parexel International, and Thermo Fisher's PPD unit, which together control roughly 35-40% share as of March 2026; Veeva Systems is a key adjacent rival in life-sciences software and analytics.
Is IQVIA laying off employees in 2026?
No mass layoffs are reported. Headcount grew to about 93,000 as of December 31, 2025, up from 88,000 in 2024, per IQVIA's 2025 Sustainability Report, though job-posting activity fell 23.3% year over year in 2025 per Revelio Labs data.
Who owns IQVIA Holdings?
IQVIA Holdings is a publicly traded company on the NYSE under ticker IQV, with no private-equity or sponsor ownership. As of July 20, 2026, its market capitalization was approximately $34.4 billion with shares trading around $205 to $206.
What legal risks does IQVIA face in 2026?
IQVIA is defending Rose et al. v. IQVIA Holdings Inc., filed April 2026 in California and removed to federal court, with an amended complaint due July 27, 2026. A separate employment discrimination suit had motions to dismiss granted in March 2026.
Timeline
  • 2026-07-28IQVIA scheduled to announce Q2 2026 results
  • 2026-03-15Launched IQVIA.ai agentic AI platform with NVIDIA, over 150 agents
  • 2026-02-24Agreed to acquire drug-discovery assets from Charles River Laboratories
  • 2026-02-04Reported FY2025 revenue of $16.310 billion, issued FY2026 guidance
  • 2025-10-08Announced $750 million acquisition of Cedar Gate Technologies
  • 2025-09-09Launched Clinical Trial Financial Suite (CTFS) platform
  • 2024-01FTC blocked IQVIA's Propel Media/DeepIntent acquisition
  • 2016-10IQVIA formed via $8.8 billion merger of Quintiles and IMS Health
Revision history
20 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
S&P GlobalMoody'sFactSet
More in Financial data and information services →
Sources